European Journal of Clinical Microbiology and Infectious Diseases

, Volume 12, Issue 10, pp 778–782

Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy

Authors

  • W. Lo
    • Department of Medical Specialities, Section of Infectious DiseasesThe University of Texas M.D. Anderson Cancer Center
  • E. Whimbey
    • Department of Medical Specialities, Section of Infectious DiseasesThe University of Texas M.D. Anderson Cancer Center
  • L. Elting
    • Department of Medical Specialities, Section of Infectious DiseasesThe University of Texas M.D. Anderson Cancer Center
  • R. Couch
    • Influenza Research CenterBaylor College of Medicine
  • F. Cabanillas
    • Department of Hematology, Section of LymphomaThe University of Texas M.D. Anderson Cancer Center
  • G. Bodey
    • Department of Medical Specialities, Section of Infectious DiseasesThe University of Texas M.D. Anderson Cancer Center
Notes

DOI: 10.1007/BF02098469

Cite this article as:
Lo, W., Whimbey, E., Elting, L. et al. Eur. J. Clin. Microbiol. Infect. Dis. (1993) 12: 778. doi:10.1007/BF02098469

Abstract

A study was conducted to determine if a two-dose regimen of influenza vaccine would enhance the immunologic response of 41 patients with lymphoma receiving chemotherapy. Hemagglutinin-inhibiting antibody responses to influenza A/H1N1, A/H3N2 and B virus occurred in 32 %, 24 % and 20 % of patients following one dose, and in 49 %, 41 % and 46 % of patients following two doses, respectively. Responses to one or more vaccine components occurred in 42 % of patients after one dose and in 71 % after two doses. Fifty percent of the patients who did not respond after one dose responded after two doses. A two-dose regimen of influenza immunization may significantly enhance the response rate of cancer patients receiving chemotherapy.

Copyright information

© Friedr. Vieweg & Sohn Verlagsesellschaft mbH 1993